MetaVia Inc. Common Stock (MTVA)

• Market cap: $12.9M
• 1 day: 0.00%
• 5 days: -8.54%
• 1 month: -9.09%
• 3 months: -31.51%
• 6 months: -58.45%
• Year to date: -28.91%
• 1 year: -66.44%
• 5 years: -99.93%
• 10 years: -99.93%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

Employees: 8

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

15% more funds holding

Funds holding: 13 [Q3] → 15 (+2) [Q4]

2.39% less ownership

Funds ownership: 12.89% [Q3] → 10.51% (-2.39%) [Q4]

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

47% less capital invested

Capital invested by funds: $3.47M [Q3] → $1.84M (-$1.63M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12 700% upside
• Avg. target: $12 700% upside
• High target: $12 700% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 39% 1-year accuracy 61 / 157 met price target

700% upside $12

Buy Initiated

30 Dec 2024